InvestorsHub Logo
Followers 57
Posts 11404
Boards Moderated 0
Alias Born 02/09/2009

Re: None

Thursday, 04/22/2021 10:20:26 AM

Thursday, April 22, 2021 10:20:26 AM

Post# of 565
Important statement from April 16, 2021 press release:

MYMD-1 has been shown to be effective in regulating the immune system from causing age-related diseases in preclinical studies. MyMD believes that it is the first oral small molecule regulator of tumor necrosis factor alpha (TNF-a) capable of crossing the blood-brain barrier. Additionally, a recent study from the Eurofins Discovery human phenotypic screening platform revealed the potential of MYMD-1 to be developed as a therapy for fibrosis.

After researching the relationships between inflammation, disease, and TNF-a, and personally witnessing the results from use of anatabine-citrate (an earlier closely related molecule), I conclude that the choice of MyMD for a company name may not be much of an exaggeration.

April 16, 2021 press release
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMD News